Annual CFO
-$293.86 M
-$12.04 M-4.27%
December 31, 2022
Summary
- As of February 23, 2025, SRNE annual cash flow from operations is -$293.86 million, with the most recent change of -$12.04 million (-4.27%) on December 31, 2022.
- During the last 3 years, SRNE annual CFO has fallen by -$120.86 million (-69.86%).
- SRNE annual CFO is now -3093331.58% below its all-time high of $9500.00, reached on December 31, 2005.
Performance
SRNE Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$55.66 M
-$6.20 M-12.54%
June 30, 2023
Summary
- As of February 23, 2025, SRNE quarterly cash flow from operations is -$55.66 million, with the most recent change of -$6.20 million (-12.54%) on June 30, 2023.
- Over the past year, SRNE quarterly CFO has dropped by -$6.20 million (-12.54%).
- SRNE quarterly CFO is now -4397.99% below its all-time high of $1.29 million, reached on June 30, 2015.
Performance
SRNE Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$234.63 M
+$25.33 M+9.74%
June 30, 2023
Summary
- As of February 23, 2025, SRNE TTM cash flow from operations is -$234.63 million, with the most recent change of +$25.33 million (+9.74%) on June 30, 2023.
- Over the past year, SRNE TTM CFO has increased by +$25.33 million (+9.74%).
- SRNE TTM CFO is now -518040.40% below its all-time high of $45.30 thousand, reached on June 30, 2009.
Performance
SRNE TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
SRNE Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -4.3% | -12.5% | +9.7% |
3 y3 years | -69.9% | -12.5% | +9.7% |
5 y5 years | -196.3% | -12.5% | +9.7% |
SRNE Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -4.3% | at low | -12.5% | +33.2% | at high | +26.6% |
5 y | 5-year | -84.2% | at low | -54.5% | +33.2% | -51.7% | +26.6% |
alltime | all time | <-9999.0% | at low | -4398.0% | +33.2% | <-9999.0% | +26.6% |
Sorrento Therapeutics Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2023 | - | -$55.66 M(+12.5%) | -$234.63 M(-9.7%) |
Mar 2023 | - | -$49.46 M(-27.6%) | -$259.96 M(-11.5%) |
Dec 2022 | -$293.86 M(+4.3%) | -$68.34 M(+11.7%) | -$293.86 M(-1.3%) |
Sep 2022 | - | -$61.17 M(-24.5%) | -$297.66 M(-6.9%) |
Jun 2022 | - | -$80.99 M(-2.8%) | -$319.60 M(+0.8%) |
Mar 2022 | - | -$83.36 M(+15.6%) | -$317.12 M(+12.5%) |
Dec 2021 | -$281.82 M(+76.7%) | -$72.14 M(-13.2%) | -$281.82 M(+12.5%) |
Sep 2021 | - | -$83.11 M(+5.9%) | -$250.55 M(+19.3%) |
Jun 2021 | - | -$78.52 M(+63.4%) | -$210.03 M(+24.2%) |
Mar 2021 | - | -$48.06 M(+17.6%) | -$169.04 M(+6.0%) |
Dec 2020 | -$159.54 M(-7.8%) | -$40.87 M(-4.0%) | -$159.54 M(+3.1%) |
Sep 2020 | - | -$42.59 M(+13.5%) | -$154.69 M(-2.1%) |
Jun 2020 | - | -$37.52 M(-2.7%) | -$157.93 M(-5.6%) |
Mar 2020 | - | -$38.55 M(+7.0%) | -$167.24 M(-3.3%) |
Dec 2019 | -$173.00 M(+54.8%) | -$36.02 M(-21.4%) | -$173.00 M(-4.9%) |
Sep 2019 | - | -$45.83 M(-2.1%) | -$181.95 M(+16.0%) |
Jun 2019 | - | -$46.83 M(+5.7%) | -$156.82 M(+18.7%) |
Mar 2019 | - | -$44.31 M(-1.5%) | -$132.11 M(+18.2%) |
Dec 2018 | -$111.77 M(+12.7%) | -$44.98 M(+117.2%) | -$111.77 M(+0.1%) |
Sep 2018 | - | -$20.70 M(-6.4%) | -$111.64 M(+7.8%) |
Jun 2018 | - | -$22.12 M(-7.7%) | -$103.60 M(+2.3%) |
Mar 2018 | - | -$23.96 M(-46.6%) | -$101.23 M(+2.1%) |
Dec 2017 | -$99.18 M(+39.8%) | -$44.85 M(+254.2%) | -$99.18 M(+40.0%) |
Sep 2017 | - | -$12.66 M(-35.9%) | -$70.84 M(-11.7%) |
Jun 2017 | - | -$19.75 M(-9.9%) | -$80.23 M(+10.4%) |
Mar 2017 | - | -$21.91 M(+32.7%) | -$72.66 M(+2.4%) |
Dec 2016 | -$70.93 M(+68.6%) | -$16.52 M(-25.1%) | -$70.93 M(+0.5%) |
Sep 2016 | - | -$22.05 M(+81.1%) | -$70.57 M(+5.5%) |
Jun 2016 | - | -$12.18 M(-39.7%) | -$66.88 M(+25.2%) |
Mar 2016 | - | -$20.19 M(+24.9%) | -$53.41 M(+27.0%) |
Dec 2015 | -$42.07 M(+46.3%) | -$16.16 M(-11.9%) | -$42.07 M(+25.3%) |
Sep 2015 | - | -$18.36 M(-1517.4%) | -$33.56 M(+61.3%) |
Jun 2015 | - | $1.29 M(-114.6%) | -$20.80 M(-27.0%) |
Mar 2015 | - | -$8.85 M(+15.6%) | -$28.49 M(-1.0%) |
Dec 2014 | -$28.76 M(+74.4%) | -$7.66 M(+36.8%) | -$28.76 M(+1.6%) |
Sep 2014 | - | -$5.60 M(-12.4%) | -$28.32 M(+10.2%) |
Jun 2014 | - | -$6.39 M(-30.0%) | -$25.70 M(+11.1%) |
Mar 2014 | - | -$9.12 M(+26.5%) | -$23.13 M(+40.3%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2013 | -$16.49 M(+334.3%) | -$7.21 M(+141.9%) | -$16.49 M(+55.5%) |
Sep 2013 | - | -$2.98 M(-21.9%) | -$10.61 M(+23.0%) |
Jun 2013 | - | -$3.81 M(+53.7%) | -$8.63 M(+57.4%) |
Mar 2013 | - | -$2.48 M(+86.8%) | -$5.48 M(+44.4%) |
Dec 2012 | -$3.80 M(+38.4%) | -$1.33 M(+33.0%) | -$3.80 M(+26.3%) |
Sep 2012 | - | -$999.40 K(+48.9%) | -$3.01 M(+15.7%) |
Jun 2012 | - | -$671.30 K(-15.8%) | -$2.60 M(-16.5%) |
Mar 2012 | - | -$797.60 K(+48.0%) | -$3.11 M(+13.5%) |
Dec 2011 | -$2.74 M(+77.4%) | -$539.00 K(-8.7%) | -$2.74 M(+17.6%) |
Sep 2011 | - | -$590.40 K(-50.2%) | -$2.33 M(+19.3%) |
Jun 2011 | - | -$1.19 M(+177.4%) | -$1.96 M(+54.4%) |
Mar 2011 | - | -$427.70 K(+232.6%) | -$1.27 M(-18.1%) |
Dec 2010 | -$1.55 M(+110.4%) | -$128.60 K(-39.5%) | -$1.55 M(-20.0%) |
Sep 2010 | - | -$212.40 K(-57.3%) | -$1.93 M(-1.6%) |
Jun 2010 | - | -$497.40 K(-29.8%) | -$1.96 M(+37.6%) |
Mar 2010 | - | -$708.30 K(+37.5%) | -$1.43 M(+94.2%) |
Dec 2009 | -$735.00 K(<-9900.0%) | -$515.10 K(+111.7%) | -$735.00 K(+1308.0%) |
Sep 2009 | - | -$243.30 K(-719.1%) | -$52.20 K(-215.2%) |
Jun 2009 | - | $39.30 K(-347.2%) | $45.30 K(-508.1%) |
Mar 2009 | - | -$15.90 K(-109.5%) | -$11.10 K(<-9900.0%) |
Dec 2008 | $0.00(-100.0%) | $167.70 K(-215.0%) | $100.00(-100.1%) |
Sep 2008 | - | -$145.80 K(+752.6%) | -$175.70 K(+312.4%) |
Jun 2008 | - | -$17.10 K(+263.8%) | -$42.60 K(-26.8%) |
Mar 2008 | - | -$4700.00(-42.0%) | -$58.20 K(-91.3%) |
Dec 2007 | -$668.10 K(<-9900.0%) | -$8100.00(-36.2%) | -$668.00 K(+1.2%) |
Sep 2007 | - | -$12.70 K(-61.2%) | -$659.90 K(+2.0%) |
Jun 2007 | - | -$32.70 K(-94.7%) | -$647.20 K(+5.3%) |
Mar 2007 | - | -$614.50 K(-6568.4%) | -$614.50 K(-6568.4%) |
Dec 2006 | $0.00(-100.0%) | - | - |
Dec 2005 | $9500.00(>+9900.0%) | $9500.00(>+9900.0%) | $9500.00(>+9900.0%) |
Sep 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
Jun 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
Mar 2005 | - | $0.00(0.0%) | $0.00(0.0%) |
Dec 2004 | $0.00(0.0%) | $0.00(0.0%) | $0.00(0.0%) |
Sep 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
Jun 2004 | - | $0.00(0.0%) | $0.00(0.0%) |
Mar 2004 | - | $0.00 | $0.00 |
Dec 2003 | $0.00 | - | - |
FAQ
- What is Sorrento Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Sorrento Therapeutics?
- What is Sorrento Therapeutics annual CFO year-on-year change?
- What is Sorrento Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Sorrento Therapeutics?
- What is Sorrento Therapeutics quarterly CFO year-on-year change?
- What is Sorrento Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Sorrento Therapeutics?
- What is Sorrento Therapeutics TTM CFO year-on-year change?
What is Sorrento Therapeutics annual cash flow from operations?
The current annual CFO of SRNE is -$293.86 M
What is the all time high annual CFO for Sorrento Therapeutics?
Sorrento Therapeutics all-time high annual cash flow from operations is $9500.00
What is Sorrento Therapeutics annual CFO year-on-year change?
Over the past year, SRNE annual cash flow from operations has changed by -$12.04 M (-4.27%)
What is Sorrento Therapeutics quarterly cash flow from operations?
The current quarterly CFO of SRNE is -$55.66 M
What is the all time high quarterly CFO for Sorrento Therapeutics?
Sorrento Therapeutics all-time high quarterly cash flow from operations is $1.29 M
What is Sorrento Therapeutics quarterly CFO year-on-year change?
Over the past year, SRNE quarterly cash flow from operations has changed by -$6.20 M (-12.54%)
What is Sorrento Therapeutics TTM cash flow from operations?
The current TTM CFO of SRNE is -$234.63 M
What is the all time high TTM CFO for Sorrento Therapeutics?
Sorrento Therapeutics all-time high TTM cash flow from operations is $45.30 K
What is Sorrento Therapeutics TTM CFO year-on-year change?
Over the past year, SRNE TTM cash flow from operations has changed by +$25.33 M (+9.74%)